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Summary. Background: Prophylaxis with either intrave-
nous (i.v.) factor VIII (FVIII) or FIX is the gold standard
of care for patients with severe hemophilia. A monoclonal
antibody (concizumab) targeting tissue factor pathway
inhibitor (TFPI) that can be administered subcutaneously
(s.c.) has the potential to alter current concepts of prophy-
laxis in hemophilia. Objectives: To evaluate the safety and
describe the pharmacokinetics and pharmacodynamics of
single-dose concizumab in healthy volunteers and patients
with hemophilia A or B.Methods: In this first human dose,
phase 1, multicenter, randomized, double-blind, placebo-
controlled trial escalating single i.v. (0.5–9000 lg kg1) or
s.c. (50–3000 lg kg1) doses of concizumab were adminis-
tered to healthy volunteers (n = 28) and hemophilia
patients (n = 24). Results: Concizumab had a favorable
safety profile after single i.v. or s.c. administration. There
were no serious adverse events and no anti-concizumab
antibodies. No clinically relevant changes in platelets, pro-
thrombin time, activated partial thromboplastin time,
fibrinogen, or antithrombin were found. A dose-dependent
procoagulant effect of concizumab was seen as increased
levels of D-dimers and prothrombin fragment 1 + 2. Non-
linear pharmacokinetics of concizumab was observed due
to target-mediated clearance. A maximum mean AUC0–∞
of 33 960 h lg mL1 and a maximum mean concentration
of 247 lg mL1 was measured at the highest dose. Conclu-
sions: Concizumab showed a favorable safety profile after
i.v. or s.c. administration and nonlinear pharmacokinetics
was observed due to target-mediated clearance. A concen-
tration-dependent procoagulant effect of concizumab was
observed, supporting further study into the potential use
of s.c. concizumab for hemophilia treatment.
Keywords: hemophilia; mAb 2021; pharmacokinetics;
safety; tissue factor pathway inhibitor.
Introduction
Severe hemophilia A and B are inherited bleeding
disorders characterized by recurrent and spontaneous
bleeding into joints, muscles, and soft tissues, resulting in
musculoskeletal damage and chronic disability. Histori-
cally, without treatment, fatal bleeding was common in
patients with severe hemophilia [1], but the availability of
high-purity clotting factor concentrates has clearly
improved their management [2]. In particular, primary
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prophylaxis with regular venous infusion of the deficient
clotting factor is recommended [3] to avoid the risk of
life- and limb-threatening bleeds. Secondary prophylaxis,
started later in life after multiple joint bleeds, and
even after the onset of joint damage, may also be benefi-
cial [4].
Despite the World Health Organization, among others,
supporting prophylaxis as the standard of care, many
patients with severe hemophilia still receive on-demand
treatment for bleeding episodes. One barrier to prophy-
lactic treatment is the requirement for venous access. This
can be problematic, especially in small children, and cen-
tral venous access devices are associated with infections
and thrombotic occlusions [5]. Another potential hin-
drance is the relatively short half-life (t½) of available
coagulation factor VIII (FVIII) and FIX products,
requiring patients to self-infuse between twice a week and
up to every second day, and having a negative effect on
compliance and quality of life [6,7]. Advances in protein
engineering have facilitated the development of FVIII
and FIX with long t½ [8–11]. While this approach has
been successful for FIX [12–15], similar gains have not
been seen for FVIII, where t½ appears to be more depen-
dent on von Willebrand factor levels [16].
There is considerable interest in alternate targets and
modes of drug administration, especially for subcutane-
ously administered agents with the potential for improved
compliance. One potential target is tissue factor pathway
inhibitor (TFPI), a multivalent, Kunitz-type proteinase
inhibitor (KPI) with three KPI domains (Fig. S1) [17,18].
TFPI is a potent inhibitor of the initiation pathway, in
which inhibition of the tissue factor–activated FVII (TF-
FVIIa) complex is dependent on FXa inhibition. TFPI
circulates in three isoforms, and the microvascular endo-
thelium is believed to be the major source of TFPI, where
it is associated with the cell surface after secretion. Fol-
lowing injury, the TF–FVIIa complex activates FIX to
FIXa and FX to FXa–this FXa generation is tightly regu-
lated by TFPI. The TFPI KPI-2 domain inhibits the
active site of FXa, enhanced by protein S. Inhibition of
the TF–FVIIa complex by TFPI requires initial binding
of KPI-2 to FXa, and subsequent formation of a TF–
FVIIa–FXa–TFPI complex, in which the KPI-1 domain
inhibits FVIIa (Fig. S1). Novo Nordisk has developed a
humanized monoclonal antibody against TFPI, con-
cizumab (mAb 2021), with high affinity for the KPI-2
domain of TFPI, the binding site of FXa (Fig. S2). By
preventing FXa binding to TFPI, concizumab also pre-
vents TFPI inhibition of TF–FVIIa complex, thereby
abrogating TFPI function as a regulator of the TF path-
way, resulting in enhanced FXa and thrombin generation
in vitro. Nonclinical studies characterizing the effect of
concizumab in vitro and in vivo [19] showed that con-
cizumab binds with high affinity to both free and cell sur-
face–bound TFPI (a substantial fraction of TFPI is
associated with endothelial cell surfaces). In hemophilia
blood and plasma, improved clot formation under hemo-
philia-like conditions was noted in a concentration-depen-
dent manner [19]. In a rabbit hemophilia bleeding model,
an intravenous (i.v.) or subcutaneous (s.c.) concizumab
dose substantially reduced cuticle bleeding, with an effect
comparable to that of recombinant FVIIa [19]. The effi-
cacy data in rabbits demonstrate the potential effect of
concizumab in efficiently preventing bleeding in hemo-
philia patients.
Monoclonal antibodies bring the advantage of a long
t½ and the possibility of s.c. administration. Thus,
concizumab may constitute a novel approach for the
management of hemophilia patients with and without
inhibitors and would present the first s.c. prophylactic
option. This report describes the first-in-human clinical
trial (explorerTM1) to investigate the safety and to describe
the pharmacokinetics (PKs) and pharmacodynamics
(PDs) of single-dose concizumab administered i.v. or s.c.
in healthy volunteers and in patients with hemophilia A
or B.
Methods
Trial design
ExplorerTM1 was a first human dose, phase 1, multicenter,
randomized, double-blind, placebo-controlled, single-dose,
dose-escalation trial. This multinational, multiethnic trial
enrolled participants at 13 sites in nine countries (Austria,
Denmark, Germany, Malaysia, South Africa, Spain, Swit-
zerland, Thailand, and the United Kingdom). ExplorerTM1
(clinicaltrials.gov identifier: NCT01228669) was approved
by local ethical committees, independent ethics commit-
tees, or institutional review boards and was conducted in
accordance with the Declaration of Helsinki and ICH
Good Clinical Practice. Written informed consent was
obtained from all participants prior to trial-related
activities.
Escalating single i.v. or s.c. doses of the trial product
were administered to healthy volunteers and patients with
hemophilia A or B according to the dosing schedule in
Fig. 1. Trial participants were assigned to the lowest ran-
domization number using a computer-generated randomi-
zation list provided by Clinical Supplies Coordination,
Novo Nordisk A/S. Within each dose cohort, trial partici-
pants were randomized 3:1 to receive a single dose of
concizumab (n = 3) or placebo (n = 1). Due to the protein
content, the appearance of reconstituted concizumab and
placebo/diluent differed. Thus, a qualified, unblinded per-
son prepared the dosing syringes, after which no differ-
ences in the appearance of the two solutions could be
seen. Investigators and trial participants were blinded to
treatment.
Dosing was initiated in healthy volunteers and, at pre-
defined switching criteria, was continued in hemophilia
patients. Switching criteria were defined as a consistent
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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increase above the normal reference range of D-dimers
and/or prothrombin fragment 1 + 2 (F1 + 2) for ≥ 24 h
in two or more healthy volunteers and/or a maximum i.v.
dose of 250 lg kg1 and a maximum s.c. dose of
1000 lg kg1 administered to healthy volunteers. Dosing
between trial participants within a dose cohort was sepa-
rated by ≥ 22 h to evaluate safety before dosing the next
trial subject in that cohort. When all trial participants in
a cohort had been dosed, a blinded safety and PK assess-
ment was performed by an internal Novo Nordisk trial
safety group prior to dose escalation. After dosing, trial
participants were monitored for 43 days.
In accordance with first human dose recommendations
from the European Medicines Agency [20], doses were
selected based on nonclinical studies and PK/PD model-
ing. Dosing was initiated at the minimum anticipated bio-
logical effect level, with 0.5 lg kg1 i.v. in healthy
volunteers. The s.c. dosing was started later, with
50 lg kg1 s.c. in healthy volunteers after safety had been
shown with the initial i.v. doses. Subsequent dose levels
were also based on PK/PD modeling.
Eligibility criteria
Eligibility criteria for healthy male volunteers and
patients with severe hemophilia A or B included age 18–
65 years, body weight 50–100 kg, and body mass index
18–30 kg m2. Healthy volunteers and hemophilia
patients were ineligible if they had a low platelet count
(< 50 000 platelets lL1), advanced atherosclerotic dis-
ease, or history or evidence of thromboembolic events/
risk (see Supporting Information for other exclusion crite-
ria).
Concomitant treatment with FVIII and FIX concentrates
Treatment of bleeds with FVIII and FIX concentrates
was allowed throughout the trial at the discretion of the
investigator. Prophylaxis with regular injections of FVIII
and FIX concentrates was allowed, except for 48 h before
and after trial drug administration.
End points
Safety (primary) The primary end point was safety,
including adverse events (AEs) over 43 days after con-
cizumab administration. Investigators were also required
to actively investigate local tolerability at injection sites.
In addition, clinical laboratory assessments (e.g. hematol-
ogy, biochemical parameters, coagulation-related para-
meters, antidrug antibodies), vital signs, physical
examination, and electrocardiogram results were
recorded.
Local injection-site reactions were evaluated based on
the following inspections: pain or tenderness, itching,
rash, redness (in mm), and induration. Coagulation-
related parameters, including platelet count, protein C
and S, prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), fibrinogen concentration, and anti-
thrombin activity were determined from citrated plasma
before dosing; at 0.5, 1, 4, 8, 12, 24, 36, and 48 h after
dosing; and at all other visits as safety markers. Coagula-
tion parameters were analyzed at a central laboratory,
whereas antithrombin was analyzed locally.
Evaluation of anti-concizumab antibodies in human
plasma was performed centrally at the screening and dos-
ing visits and 28 and 43 days after administration of trial
product, using a bridging enzyme-linked immunosorbent
assay (ELISA), with biotin-labeled concizumab for anti-
body capture and peroxidase-labeled concizumab for
detection of bound anti-concizumab antibodies. Samples
were tested in a tiered approach including screening and a
confirmatory test.
Pharmacokinetics Blood samples for PK assessments
were collected throughout the trial: predose and at 0 (i.e.
completion of injection), 5, 15, and 30 min; 1, 4, 8, 12,
24, 36, and 48 h; and 3, 4, 5, 6, 7, 10, 14, 21, and 43 days
postdosing. Blood samples from 5 and 15 min were not
taken for PK assessment after s.c. administration.
Plasma concizumab concentrations were determined
centrally using an ELISA, which measured free con-
cizumab and concizumab in a 1:1 complex with TFPI.
PK endpoints included total exposure (AUC0–∞), maxi-
mum plasma concentration (Cmax), clearance (CL), t½,
mean absorption time, volume of distribution at steady
i.v. dose 7Safety assessment
Healthy volunteers; 1 site
9000 µg kg–1
i.v. dose 6
3000 µg kg–1 3000 µg kg–1
i.v. dose 5
1000 µg kg–1 1000 µg kg–11000 µg kg–1
i.v. dose 4
250 µg kg–1
i.v. dose 4
250 µg kg–1
s.c. dose 2
s.c. dose 3 s.c. dose 3
s.c. dose 4
s.c. dose 1
250 µg kg–1
i.v. dose 3
50 µg kg–1 50 µg kg–1
i.v. dose 2
5 µg kg–1
i.v. dose 1
n = 16 HV i.v. n = 12 HV s.c.n = 16 patients i.v. n = 8 patients s.c.
0.5 µg kg–1
Hemophilia patients; 12 sites
Fig. 1. ExplorerTM1 dosing schedule. Four healthy volunteers (HV)
or hemophilia patients were randomized in each cohort (concizumab,
n = 3; placebo, n = 1). Each participant received one dose of placebo
or concizumab. All participants (28 healthy volunteers and 24 hemo-
philia patients) completed the trial, and were included in the full
analysis set and safety analysis.
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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state, bioavailability, and time to maximum concentration.
Only the results of key PK parameters are presented.
Pharmacodynamics PD parameters were assessed up to
43 days postdosing at the same time points as the PK
assessments. Free TFPI in plasma (i.e. TFPI not bound
to concizumab) was investigated at each trial visit using
an ELISA kit (Asserachrom TFPI, Diagnostica Stago,
Asnieres-sur-Seine, France). Residual TFPI functionality
in plasma was determined by detecting FXa activity with
a chromogenic assay kit and reported as U mL1 (S2222;
Chromogenix, DiaPharma Group, Inc., West Chester,
OH, USA). FXa generation is inversely proportional to
free TFPI concentration with increasing drug levels asso-
ciated with increased FXa generation.
D-dimer and prothrombin F1 + 2 concentrations were
assessed as markers of procoagulant effect.
Statistical analysis
The sample size (four participants per cohort: three con-
cizumab and one placebo) was chosen to enable adequate
evaluation of safety and tolerability, while ensuring that
the smallest possible number of trial participants were
exposed to the investigational drug.
Safety analyses were based on descriptive statistics. PK
parameters were determined using non-compartmental
methods (via SAS version 9.3, SAS Institute, Cary, NC,
USA); dose linearity for PK was evaluated based on Cmax
and AUC0–∞, and was assessed separately within i.v. and
s.c. cohorts by analysis of variance on the log-transformed
parameter values, using log-transformed dose as the co-
variate. Slope estimates were provided with 95% confi-
dence intervals. PK parameters were estimated only for a
trial subject if the plasma concentrations of concizumab
recorded made it scientifically meaningful. All derived PK
parameters were summarized by dose cohort. PD parame-
ters were based on descriptive statistics, including graphs,
and summarized by dose cohort and time point.
Results
Trial population
The trial was conducted from October 25, 2010, to Sep-
tember 10, 2012. Of 213 screened subjects, 143 healthy
volunteers and 18 hemophilia patients did not meet the
eligibility criteria. In total, 52 subjects (28 healthy male
volunteers and 24 hemophilia patients: 21 with hemo-
philia A and three with hemophilia B) were randomized
(Fig. 1); none had inhibitor titer > 0.6 BU. There were no
withdrawals, and all participants were included in the full
analysis set and safety analysis.
There were no significant differences in demographics
and baseline characteristics between healthy volunteers
and hemophilia patients or between s.c. and i.v. adminis-
tration. In the four cohorts (healthy volunteers i.v. and
s.c. and hemophilia patients i.v. and s.c.), mean age, body
weight, and body mass index ranged from 30–36 years,
71–77 kg, and 24–26 kg m2, respectively. None of the
trial participants had clinical signs of inflammation at
screening or during the study.
Safety
No serious AEs were reported during the trial (up to
43 days postdosing) in either healthy volunteers or hemo-
philia patients. No anti-concizumab antibodies were
detected.
Across all dose cohorts, 76 AEs were reported in 34 of
the 52 trial participants (Table 1). Of these, 57 (75%)
were mild, 17 (22%) were moderate, and 2 (3%) were
graded as severe (1 endodontic procedure in a hemophilia
patient given placebo s.c., and 1 case of sciatica in a
hemophilia patient given concizumab 9000 lg kg1 i.v.).
However, both serious AEs were considered unlikely to
be related to concizumab/placebo. All eight AEs in the
highest i.v. dose cohort (9000 lg kg1) occurred in 1
patient and were of a different nature. Of the 76 AEs, 19
occurred in the placebo groups.
Across all dose cohorts, five AEs were judged by inves-
tigators as possibly or probably treatment related, of
which one mild and one moderate AE occurred in the
placebo group and one moderate and two mild AEs
occurred after concizumab administration. The moderate
AE in the concizumab group was a small superficial
thrombophlebitis in a healthy volunteer in the
1000 lg kg1 s.c. cohort, manifesting as local skin tender-
ness 5 days post drug administration, and diagnosed with
ultrasound as a short segment (1 mm thick and 1–2 cm
long) of non-compressible, superficial vein corresponding
with the point of tenderness. The symptoms disappeared
spontaneously without treatment the day after diagnosis.
The mild AEs were trace protein in urine and abdominal
pain in hemophilia patients receiving 250 and
9000 lg kg1 i.v. concizumab, respectively. In the placebo
group, the moderate treatment-related AE was an allergic
skin reaction in a hemophilia patient on the left arm and
left cheek a few hours post i.v. administration that disap-
peared 2 days later with treatment, and the mild treat-
ment-related AE was injection-site discomfort in a
healthy volunteer following s.c. placebo administration.
There was no apparent dose relationship with respect
to the number of AEs observed. Additionally, there was
no indication of a higher incidence of AEs in hemophilia
patients than in healthy volunteers, except for bleeding
episodes (19 AEs in patients, 0 AEs in healthy volunteers)
and pain (eight AEs in patients, one AE in healthy
volunteers)―both AEs that are related to hemophilia
itself rather than to treatment (Table 1).
Local injection-site reactions were few: 65 mild reac-
tions and one moderate reaction were reported in 19 trial
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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participants from a total of 3331 reported assessments in
the trial. No clinically relevant changes in vital signs, elec-
trocardiogram, or physical examination were reported fol-
lowing concizumab administration.
Biochemical markers including sodium, potassium, cre-
atinine, albumin, total bilirubin, aspartate aminotransfer-
ase, alanine aminotransferase, c glutamyltransferase,
alkaline phosphatase, and C-reactive protein were within
normal limits throughout the trial. No noteworthy change
was apparent for troponin T levels, although three sub-
jects who were dosed s.c. at 1000 or 3000 lg kg1 had
marginally raised values, which were transient. Abnormal
ECG recordings observed were not considered clinically
significant or related to concizumab.
No clinically relevant changes in platelets, PT, aPTT,
protein C and S, or antithrombin were observed. Fibrino-
gen levels showed high intrasubject and intersubject varia-
tion without following a trend in connection to specific
concizumab exposure levels (Fig. S3). Five healthy volun-
teers and three hemophilia patients had a fibrinogen value
< 1.5 g L1. All five healthy volunteers had baseline
fibrinogen < 2 g L1, and the lowest was 1.15 g L1. The
percentage change was between 0% and 30%, and maxi-
mum change was often noted in the first week postinfu-
sion. Among the hemophilia patients, two patients in the
i.v. cohort receiving 1000 and 3000 lg kg1 showed a
~ 50% decrease in the first 10 days of the trial. High intra-
subject and intersubject variations in the data were com-
mon, with some patients showing a significant decrease.
For all observations, there were no signs or symptoms
indicative of disseminated intravascular coagulation.
Pharmacokinetics
Concizumab was detected in plasma up to 43 days after
dosing (Fig. 2); the plasma concentration profiles suggest
Table 1 Treatment-related and most common AEs following i.v. and s.c. administration of concizumab or placebo in healthy volunteers and
hemophilia patients
Treatment Total
Healthy volunteers
Concizumab, lg kg1
Hemophilia patients
Concizumab, lg kg1
Healthy
volunteers
Hemophilia
patients
0.5 5 50 250 1000 250 1000 3000 9000 Placebo Placebo
i.v. administration
Trial participants (n) 32 3 3 3 3 – 3 3 3 3 4 4
Trial participants with AEs (n) 19 2 1 0 2 – 3 2 3 1 2 3
Total AEs (n) 37 2 1 0 3 – 5 5 3 8 2 8
Severe 1 0 0 0 0 – 0 0 0 1 0 0
Moderate 11 1 0 0 1 – 1 2 2 2 0 2
Mild 25 1 1 0 2 – 4 3 1 5 2 6
Treatment-related AEs (n) 3 0 0 0 0 – 1
(mild)
0 0 1
(mild)
0 1
(moderate)
Most common AE (n)
Headache, common cold, fatigue, or flu 8 2 1 0 1 – 0 1 0 2 1 0
Pain
Musculoskeletal 3 0 0 0 0 – 0 0 1 1 0 1
Other 4 0 0 0 0 – 0 0 1 2 0 1
Bleeding
Joint 7 0 0 0 0 – 2 1 0 1 0 3
Other 3 0 0 0 0 – 2 0 0 0 0 1
s.c. administration
Trial participants (n) 20 – – 3 3 3 – 3 3 – 3 2
Trial participants with AEs (n) 15 – – 2 1 3 – 3 2 – 2 2
Total AEs (n) 39 – – 5 1 6 – 13 5 – 3 6
Severe 1 – – 0 0 0 – 0 0 – 1 0
Moderate 6 – – 1 0 2 – 2 0 – 0 1
Mild 32 – – 4 1 4 – 11 5 – 3 4
Treatment-related AEs (n) 2 – – 0 0 1
(moderate)
– 0 0 – 1
(mild)
0
Most common AE (n)
Skin sign or symptom 4 – – 1 0 0 – 1 0 – 0 2
Pain
Musculoskeletal 1 – – 0 0 1 – 0 0 – 0 0
Other 1 – – 0 0 0 – 1 0 – 0 0
Bleeding
Joint 7 – – 0 0 0 – 4 2 – 0 1
Other 2 – – 0 0 0 – 0 1 – 0 1
AE, adverse event; i.v., intravenous; s.c., subcutaneous.
© 2015 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
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the presence of nonlinear PK, with a switch from fast
clearance at low concentrations to a longer t½ at higher
concentrations of concizumab. The nonlinear characteris-
tics were confirmed by PK analysis (Table 2): AUC0-∞
and Cmax increased with increasing dose in a greater than
dose-dependent fashion after i.v. and s.c. dosing in both
healthy volunteers and hemophilia patients.
Consistent with target-mediated clearance [21], at low
concizumab concentrations, binding to TFPI has a signifi-
cant impact and there was faster than linear clearance; at
high concizumab concentrations, a more linear clearance
was observed (Table 2). Maximum mean values for
AUC0-∞ and Cmax were obtained in the highest dose
cohorts of concizumab following i.v. administration
(33 960 h lg mL1 and 247 lg mL1, respectively, for
9000 lg kg1 i.v.) and s.c. administration
(2452 h lg mL1 and 16.7 lg mL1, respectively, for
3000 lg kg1 s.c.) in hemophilia patients (Table 2). In a
dose-proportional context, Cmax would be dose dependent
and mean residence time (MRT), t½, and CL would be
dose independent, whereas for concizumab all four
parameters were observed to be strongly dose related.
After i.v. administration in patients, mean t½ ranged from
31.1 to 74.2 h, while mean MRT ranged from 9.1 to
162 h.
The PK of concizumab was similar in healthy volun-
teers and hemophilia patients at the dose levels investi-
gated in both populations (250 lg kg1 i.v. and
1000 lg kg1 s.c.). Slight differences in PK between
healthy volunteers and hemophilia patients after s.c. dos-
ing were probably due to variability of response to mode
of administration rather than to differences in response
between the two cohorts.
Pharmacodynamics
Free TFPI plasma concentrations decreased dose-depen-
dently in both healthy volunteers and hemophilia patients
after i.v. and s.c. concizumab administration (Fig. 3).
Free plasma TFPI profiles were inversely related to PK
profiles (i.e. TFPI concentration decreased with increasing
concizumab concentration in plasma; Fig. 4) and
remained decreased for ≥ 14 days postdosing at the high-
est dose levels.
Residual functional TFPI levels in plasma decreased in
a concentration-dependent manner with increased con-
cizumab exposure in both healthy volunteers and hemo-
philia patients. This decrease was observed at i.v. doses
≥ 250 lg kg1 and at s.c. doses ≥ 1000 lg kg1 (data not
shown).
Coagulation activation parameters
Dose-dependent increases in D-dimer and F1 + 2 levels
were observed, indicating a procoagulant effect of con-
cizumab (Figs 5 and 6). These dose-dependent increases
were generally observed at i.v. doses of concizumab
≥ 250 lg kg1 in healthy volunteers, with a more pro-
nounced effect seen in hemophilia patients only at higher
i.v. doses (1000, 3000, and 9000 lg kg1). Increases in D-
dimer in hemophilia patients and healthy volunteers were
higher with i.v. doses than with comparable s.c. doses;
this blunting to s.c. dosing may be related to the lower
peaks achieved with s.c. doses. D-dimer responses in
hemophilia patients were smaller than those in healthy
volunteers at the same dose level; the same D-dimer con-
centration (ng mL1) required an ~ 36-fold higher dose in
hemophilia patients than in healthy volunteers. In con-
trast, F1 + 2 increases showed a tendency toward dose
dependency regardless of whether they were measured in
healthy volunteers or hemophilia patients (Fig. 6).
A positive correlation was demonstrated between
plasma concizumab concentrations and D-dimer and
F1 + 2 levels (Fig. S4A); with increasing plasma con-
cizumab levels, the levels of D-dimer and F1 + 2
increased.
As expected, an inverse correlation was demonstrated
between both D-dimer and F1 + 2 levels and free TFPI
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Fig. 2. Mean PK profiles of concizumab concentration (log scale) up
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cebo to healthy volunteers and hemophilia patients.
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plasma concentrations (Fig. S4B). The highest increases
of D-dimers and F1 + 2 were observed when TFPI could
no longer be detected by the TFPI ELISA, suggesting
potential saturation of plasma TFPI pool and inhibition
of TFPI associated with microvasculature.
Bleeding events
Twenty-four bleeds/bruises occurred in 14 hemophilia
patients (nine concizumab; five placebo), and one bruise
was reported in a healthy volunteer given concizumab
(Table S1). None of the bleeds occurred at high con-
cizumab levels and low free TFPI plasma concentra-
tions, except a bleed caused by a minor finger cut
(Fig. 4).
Discussion
This trial was the first to assess the safety, PK, and PD
of single-dose concizumab in humans. Importantly, there
were no safety concerns with concizumab after i.v. or s.c.
administration. There were no serious or severe treat-
ment-related AEs, and no antidrug antibodies were
detected. Local injection-site reactions were few; one
moderate reaction, a superficial thrombophlebitis in a
healthy volunteer in the 1000 lg kg1 s.c. cohort, was
manifest as local skin tenderness 5 days postdrug admin-
istration, which quickly disappeared spontaneously.
Nonlinear PK of concizumab was observed after i.v.
and s.c. dosing in healthy volunteers and patients, reflect-
ing dose-dependent, target-mediated clearance at low
doses. Target-mediated clearance is commonly observed
with monoclonal antibodies and indicates that binding of
the drug (monoclonal antibody) to its target influences
drug distribution and/or elimination and consequently the
drug concentration. Thus, low concizumab concentrations
were associated with faster clearance due to binding to
TFPI, and high concizumab concentrations were associ-
ated with a slower clearance typical of monoclonal anti-
bodies since clearance via the target contributes less to
the overall clearance at high drug concentrations.
Free TFPI plasma concentrations and residual TFPI
functional levels decreased in a concizumab concentra-
tion-dependent manner in healthy volunteers and hemo-
philia patients after i.v. and s.c. administration.
Post concizumab administration, there were no clini-
cally relevant changes in platelets, PT, aPTT, and anti-
thrombin. There was a decrease in mean fibrinogen
concentration, which continued to be within normal
range. Furthermore, interindividual variability in fibrino-
gen levels was common, with some patients in the highest
dose cohort showing a significant decrease. As expected,
there was a dose-dependent procoagulant effect of con-
cizumab, seen as increased levels of D-dimers and pro-
thrombin F1 + 2; although indirect, this evidence
confirms the procoagulant activity of concizumab.
At similar dose levels the procoagulant response was
greater in healthy volunteers than hemophilia patients,
and the magnitude of response appeared to be more pro-
nounced with i.v. than s.c. administration. The latter is
potentially due to slower absorption of the antibody, with
lower peak levels and lesser inhibition of TFPI. Further
peak responses were beyond the measurable range of the
TFPI assay―consistent with the known distribution of
the TFPI, where more than 50–80% is associated with
endothelium [22].
Table 2 Mean PK parameters of concizumab following i.v. and s.c. administration in healthy volunteers and hemophilia patients
Concizumab cohort,
lg kg1
Cmax, ng mL
1 AUC0–∞, h ng mL
1 MRT, h t½, h CL (i.v.), mL h
1 kg1
Mean (CV, %) Mean (CV, %) Mean (SD) Mean (SD) Mean (SD)
Healthy volunteers i.v.
0.5 6.23 (15.3) 0.29 (11.1) 0.11 (0.03) – 1754 (175)
5 47.9 (36.7) 36.1 (81.0) 0.73 (0.46) – 220 (167)
50 792 (16.0) 1578 (33.6) 6.63 (3.42) – 35 (13.4)
250 4462 (5.9) 44 932 (15.1) 8.89 (0.35) 25.7 (1.12) 5.83 (0.97)
Hemophilia patients i.v.
250 4008 (8.7) 38 385 (9.8) 9.13 (1.06) 31.1 (3.84) 6.56 (0.73)
1000 35 525 (14.7) 1 202 469 (24.5) 35.3 (2.13) 49.5 (4.85) 0.93 (0.23)
3000 74 367 (3.1) 5 191 678 (9.3) 68.9 (2.21) 74.2 (16.1) 0.57 (0.07)
9000 247 104 (30.8) 33 960 277 (30.0) 162 (20.4) 65.9 (11) 0.28 (0.08)
Healthy volunteers s.c.
50 9.16 (27.3) – – – –
250 35.9 (18.8) 10 772 (93.4) 274 (246) 90.3 (18.2) 37.5 (22.7)
1000 999 (42.7) 54 695 (36.8) 85.9 (22.3) 114 (5.46) 19.9 (6.71)
Hemophilia patients s.c.
1000 1791 (88.6) 109 350 (70.8) 126 (137) 116 (69.4) 17.2 (17.9)
3000 16 689 (42.4) 2 452 323 (52.0) 105 (11) 74.8 (31.4) 1.63 (1.17)
CL, clearance; CV, coefficient of variation; i.v., intravenous; PK, pharmacokinetics; MRT, mean residence time; s.c., subcutaneous; SD, stan-
dard deviation; t½, terminal half-life.
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The PK profile observed in rabbits similarly revealed a
nonlinear, dose-dependent profile, consistent with a
target-mediated clearance [21]. Further, rabbit and rat
models investigating the biodistribution of concizumab by
immunohistology showed marked co-localization of con-
cizumab with endogenous rabbit TFPI on the endothe-
lium of the microvasculature with negligible
subendothelial build-up [23].
In a monkey model the maximum target clearance
was estimated at 11 lg h1 kg1 and the Km (the con-
centration at which the target-mediated elimination rate
is 50% of the maximum) for concizumab was
0.54 lg mL1 where the nonlinear part of the clearance
predominates [21]. The data suggest that TFPI, the tar-
get for concizumab, constitutes a pool with a consider-
able capacity for clearance of the administered
antibody.
Regarding bleeding events, none occurred at high con-
cizumab levels or low free TFPI plasma concentrations,
except a minor finger cut. Although bleeds are expected
as a part of the patients’ underlying hemophilia, bleeds
were reported as AEs. This trial was not aimed at evalu-
ating hemostatic efficacy on bleeding rate, and patients
were allowed to treat themselves with their standard
FVIII or FIX concentrate both on demand and prophy-
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lactically. Therefore, the bleeding data must be inter-
preted with caution.
Monoclonal antibodies have several potential advanta-
ges in the treatment of patients with hemophilia, includ-
ing s.c. administration. Importantly, antibody therapy is
not associated with the development of inhibitors against
coagulation factors. Other advantages of antibody drugs
include good solubility and stability, a long plasma t½,
high selectivity, and specificity [24].
Due to its mode of action, concizumab has the poten-
tial to prevent bleeding in both hemophilia A and B, irre-
spective of inhibitor status or severity. For the first time,
venous access is not required with this hemophilia treat-
ment, with potential for improved patient compliance
and, therefore, outcomes.
These data should be viewed in light of the limited size
of the cohorts and the single-dose exposure. However,
this first-in-human clinical trial generated valuable PK
data, and will provide the basis for future safety and effi-
cacy trials. Clinical trials are required to confirm the he-
mostatic efficacy of concizumab in patients with
hemophilia and to define the therapeutic window of TFPI
inhibition. The dose-finding studies will need to address
the impact of target-mediated clearance on frequency of
administration and dosing of concizumab, and its clinical
application regarding prophylaxis and bleeding.
In conclusion, concizumab has the potential to alter
current concepts of prophylaxis in patients with hemo-
philia. There were no safety concerns with concizumab
after i.v. or s.c. administration in healthy volunteers or in
patients with hemophilia. PK investigations showed that
concizumab was influenced by target-mediated clearance.
A concentration-dependent effect was observed on plasma
TFPI functionality and levels. The results of ExplorerTM1
are promising, and the potential use of s.c. concizumab
for hemophilia treatment warrants further study.
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